Skip to main content
main-content

The independent medical news service

30-06-2020 | Oncology | News | Article

Salvage nivolumab–ipilimumab shows potential for some metastatic RCC patients

The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.

17-06-2020 | Oncology | News | Article

Immunotherapy de-escalation in advanced RCC not feasible yet

Results from two studies presented at the virtual 2020 ASCO Annual Meeting suggest that the strategy of using single-agent nivolumab followed by response-adaptive or salvage add-on ipilimumab cannot be recommended for patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | Oncology | News | Article

RCC studies identify biomarkers of PD-1 inhibitor outcomes

Analyses of the CheckMate 025 and KEYNOTE-427 trials of nivolumab and pembrolizumab, respectively, have identified biomarkers associated with response to the individual agents in patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | Oncology | News | Article

Second-line lenvatinib–pembrolizumab shows promise for metastatic ccRCC

Research suggests that patients with metastatic clear cell renal cell carcinoma with disease progression after immune checkpoint inhibitor therapy may benefit from the combination of lenvatinib and pembrolizumab.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

09-06-2020 | Oncology | News | Article

KEYOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

04-06-2020 | Oncology | News | Article

HIF-2α inhibition ‘promising’ for von Hippel–Lindau disease-associated RCC

Findings from an open-label phase 2 study suggest the first-in-class HIF-2α inhibitor MK-6482 has “promising efficacy and tolerability” in the treatment of renal cell carcinoma associated with von Hippel–Lindau disease.